ImmunityBio Inc IBRX 深 沪
等待开盘 02-07 09:30:00 美东时间
5.655
+0.015
+0.27%
华盛通- 最 高8.28
- 今 开5.70
- 成交量 283.56万股
- 最 低 1.95
- 昨 收 5.64
- 总市值 225.07万
- 52周最高 8.28
- 市盈率 静 --
- 换手率 712.46%
- 52周最低 0.00
- 委 比 38.43%
- 总股本 0.00亿
- 历史最高 8.28
- 量 比 0.59
- 振 幅 112.23%
- 历史最低 0.00
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So
Hedge funds have been anticipating a surge in ImmunityBio's revenue, which has grown by 700% year-over-year.
01-17 00:04
Looking For A Short Squeeze? 10 Stocks Ready To Rocket
Here's a look at the top 10 most heavily shorted stocks, including Lucid, MARA, Avis, Kohl's and Hims & Hers Health.
01-16 23:41
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-16 01:35
Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 300 points ...
01-15 23:28
ImmunityBio Reports Q4 Preliminary Net Product Revenue Of ~#38.3M,
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025.
01-15 21:35
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in BCG-unresponsive non-muscle invasive bladder cancer.
2025-12-13 01:00
ImmunityBio Presents Long-Term Overall Survival Data In Non-Small Cell Lung Cancer Patients And Announces Registrational Intent Phase 3 Trials With ANKTIVA And Checkpoint Immunotherapy At World Conference On Lung Cancer
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such
2024-09-09 20:36
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Nikola Corporation (NASDAQ:NKLA) fell sharply in Monday's session after the company announced it entered into a securities purchase agreement and filed for a mixed shelf offering. Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in today’s mid-day session. G...
2024-08-20 01:37
Piper Sandler Maintains Neutral on ImmunityBio, Lowers Price Target to $4.75
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and lowers the price target from $6 to $4.75.
2024-08-20 00:28
